dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 122 | |
4 mg | In stock | $ 207 | |
8 mg | In stock | $ 331 | |
20 mg | In stock | $ 636 | |
40 mg | In stock | $ 992 |
Description | dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis. |
Targets&IC50 | BET:430 nM (EC50) |
In vitro | dBET1 induced a potent and superior inhibitory effect on MV4;11 cell proliferation at 24 hours (measured by ATP content, IC50 = 0.14 μM, compared to IC50 = 1.1 μM with JQ1) consistent with the reported, pronounced inhibitory effect of RNA silencing of BRD4 in this and other models of MLL-rearranged leukemia. |
CAS No. | 1799711-21-9 |
Chemical Formula | C38H37ClN8O7S |
Molecular Weight | 785.27 |
Solubility | DMSO: 50 mg/mL H2O: Insoluble; Ethanol: 5 mg/mL |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom